The central hypothesis of this project is that a developing joint or skeletal anlage from one species may serve as a morphogenic scaffold for chondrocytes from another species. The anlage will be rendered devoid of innate viable chondrocytes and seeded with chondrocytes from another organism for culture. The source of the viable chondrocytes and thus the cell surface antigens within this engineered growing joint or anlage could therefore be selected. Transplanatation of the engineered construct back into the organism from which the viable chondrocytes had been obtained would be useful in orthopedic and maxillofacial reconstructive surgery. It is our belief that the information obtained from the proposed studies will be translated for clinical application within a short period of time. Our hypothesis will be tested with three major Specific Aims (SA): SA I: The effect of developmental age and thus matrix composition of developing joint scaffolds on the permeation of xenogeneic chondrocytes throughout them will be characterized. SA II: The in vitro growth of engineered joints will be measured. SA III: The fate of in vitro engineered joints in surgical models will be assessed. These studies will first use bovine chondrocytes/chick joint scaffolds because of their low cost. Once technical parameters are defined, mouse chondrocytes/rat joint scaffolds and pig chondrocytes/pig joint scaffolds will be used in preparation for in vivo models. Methods for the in vitro studies include histomorphometric, biochemical and molecular analysis of chondrocyte function. In vivo fate of engineered joints will be assessed in our model of murine joint transplantation and will be further verified in the pig.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR045870-02
Application #
6055735
Study Section
Special Emphasis Panel (ZHL1-CSR-F (M2))
Program Officer
Panagis, James S
Project Start
1998-09-01
Project End
2003-03-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Glowacki, J; Yates, K E; Maclean, R et al. (2005) In vitro engineering of cartilage: effects of serum substitutes, TGF-beta, and IL-1alpha. Orthod Craniofac Res 8:200-8
Zhou, Shuanhu; Lechpammer, Stanislav; Greenberger, Joel S et al. (2005) Hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-beta/Smad3 signaling. J Biol Chem 280:22688-96
Yates, Karen E; Allemann, Florin; Glowacki, Julie (2005) Phenotypic analysis of bovine chondrocytes cultured in 3D collagen sponges: effect of serum substitutes. Cell Tissue Bank 6:45-54
Zhou, Shuanhu; Yates, Karen E; Eid, Karim et al. (2005) Demineralized bone promotes chondrocyte or osteoblast differentiation of human marrow stromal cells cultured in collagen sponges. Cell Tissue Bank 6:33-44
Warden, Scott; Zaleske, David J; Glowacki, Julie (2004) Fate of a chimeric joint construct in an ectopic site in SCID mice. Cell Transplant 13:161-8
Zaleske, D; Peretti, G; Allemann, F et al. (2003) Engineering a joint: a chimeric construct with bovine chondrocytes in a devitalized chick knee. Tissue Eng 9:949-56
Glowacki, J; Yates, K E; Warden, S et al. (2002) Engineering a biological joint. Ann N Y Acad Sci 961:123-5
Allemann, F; Mizuno, S; Eid, K et al. (2001) Effects of hyaluronan on engineered articular cartilage extracellular matrix gene expression in 3-dimensional collagen scaffolds. J Biomed Mater Res 55:13-9